Combining Semaglutide with Anti-Amyloid Treatments for Alzheimer's Disease
Official title: Combination Therapy with Semaglutide and Anti-Amyloid Antibodies for Alzheimers Disease
Funded at Brigham and Women's Hospital · NIH-11015826 · Data updated 2026-11-12
This study is looking at whether taking semaglutide, a medication for diabetes and weight loss, along with special antibodies can help improve thinking and memory for people with early-stage Alzheimer's disease, while also making treatment safer and more effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | February 1, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $765,619 |
| NIH project number | 5R01AG084531-02 |
| Project ID | NIH-11015826 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with early-stage Alzheimer's disease who may also have conditions like Type 2 diabetes or obesity.
✕Less likely to help
Patients with advanced Alzheimer's disease or those who do not have the ApoE4 genetic variant may not benefit from this research.
What this research studies
This research investigates the effects of combining semaglutide, a medication typically used for diabetes and obesity, with anti-amyloid antibodies to improve treatment outcomes for early-stage Alzheimer's disease. The approach aims to enhance cognitive function while minimizing side effects associated with current anti-amyloid therapies. By leveraging semaglutide's neuroprotective and anti-inflammatory properties, the study seeks to address the limitations of existing treatments and improve patient safety. Participants may receive a combination of these therapies to evaluate their effectiveness in slowing cognitive decline.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with early-stage Alzheimer's disease.
How similar studies have gone: Previous studies have shown promising results with GLP-1 receptor agonists in Alzheimer's models, indicating potential for success with this combined approach.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Lemere, Cynthia a — Brigham and Women's Hospital
- Study coordinator: Lemere, Cynthia a
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Cognitive SuperAging: Exploring why some octogenarians stay sharp in memory
This NIH grant studies why a small group of people aged 80+ keep memory skills as good as much younger people, hoping to understand how to protect memory as we age.
-
CLU's role in Alzheimer's disease pathogenesis
Researchers are studying how the CLU gene may drive brain changes in Alzheimer's disease and how targeting CLU could lead to safer treatments.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.